
VolitionRx chief hails importance of colorectal cancer screening test CE mark
The boss of cancer diagnostics group VolitionRx (NYSE:VNRX) reckons the awarding of a CE mark for its Nu.Q Colorectal Cancer Screening Triage test could be transformational for the firm. Chief executive Cameron Reynolds tells Proactive: “This is a very big deal for us. It really shifts the company from an R&D company to a product […]
Recent Comments